C-C motif chemokine 4 (CCL4)

C-C motif chemokine 4 (CCL4), historically known as macrophage inflammatory protein-1 beta (MIP-1 beta), is a small cytokine belonging to the CC chemokine subfamily [2, 4]. It is primarily produced by macrophages, dendritic cells, and lymphocytes in response to inflammatory stimuli or mitogens [14, 19]. CCL4 acts as a potent chemoattractant for immune cells such as natural killer cells, monocytes, and T lymphocytes, primarily through its high-affinity interaction with the G protein-coupled receptor CCR5 [1, 2]. By facilitating the recruitment of these effector cells, CCL4 plays a crucial role in orchestrating both innate and adaptive immune responses and maintaining tissue homeostasis [2, 7]. In clinical pathology, dysregulated CCL4 signaling is implicated in various conditions, including chronic inflammatory diseases, atherosclerosis, and cancer progression, where it can recruit immunosuppressive cells to the tumor microenvironment [6, 16, 18]. Interestingly, CCL4 also serves as a major endogenous suppressor of HIV-1 by competitively binding to CCR5, one of the primary coreceptors for viral entry into CD4+ T cells [2, 20]. While direct CCL4-targeting therapeutics are primarily in experimental or preclinical stages, the CCL4-CCR5 axis is successfully targeted by drugs such as maraviroc, a CCR5 antagonist used in HIV treatment [12, 16]. Additionally, serum CCL4 levels are increasingly recognized as valuable biomarkers for monitoring disease activity and therapeutic response in airway inflammation and certain hematologic malignancies [8, 19].

Other names

Macrophage inflammatory protein-1 betaMIP-1-betaMIP-1 betaACT2ACT-2Small-inducible cytokine A4SCYA4Lymphocyte activation gene 1 proteinLAG-1LAG1HC21G-26 T-lymphocyte-secreted proteinT-cell activation protein 2

Neutralization of the chemokine ligand to prevent receptor binding; Antagonism of the CCR5 receptor to block ligand-induced signaling.